Federal Court Judge Focuses Amgen EPO Patent
Infringement Trial on Four of Five Patents
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--June 9, 2000--Amgen (Nasdaq:AMGN - news) today announced that,
in the ongoing patent infringement litigation with Hoechst Marion Roussel (HMR, now known as Aventis) and Transkaryotic
Therapies (TKT), Judge William G. Young of the U.S. District Court of Massachusetts in Boston today issued a preliminary
ruling granting Hoechst and TKT's motion for noninfringement of U.S. Patent No. 5,618,698, one of the five Amgen patents in
suit. While the Court also held that the HMR/TKT EPO product does not literally fall within the scope of Amgen U.S. Patent
No. 5,621,080, it may, nonetheless, infringe if the HMR/TKT EPO product is equivalent to the product claimed by the `080
patent. Judge Young denied Hoechst and TKT's motion for noninfringement of the U.S. Patent No. 5,547,933.
The trial on infringement of the remaining four Amgen EPO patents continues on Monday, June 12. The Court previously ruled
that HMR/TKT infringe claim 1 of U.S. Patent No. 5,955,422.
biz.yahoo.com |
